A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Inclusion Criteria: * Male or female patients, 50 to 85 years of age at screening visit * Subject has signed the Informed Consent form * Subjects with Non-Exudative AMD having ETDRS BCVA between 33 and 72 letters read (equivalent to 20/40 - 20/200 on Snellen Chart) with the level of vision caused by the non-exudative AMD and no other factor/s * Subjects with symptomatic decrease in visual acuity in the last 12 months * Subjects with combination of areas of RPE disturbances (hyper or hypopigmentation) and/or \> 1 large druse(n) (\>125 microns) and/or multiple intermediate drusen (62-124 microns) in the macula as confirmed by the central reading center * Subjects with evidence of reasonably well-preserved areas of RPE by clinical examination and well-defined RPE and outer segment ellipsoid line by OCT examination in the central 1 mm of the macula as confirmed by the central reading center. More specifically, reasonable reasonably well- preserved central 1 mm of the macula means: * The RPE and outer retinal layers throughout the central 1 mm are intact * No signs of NVAMD such as intraretinal or sub retinal fluid, or sub retinal hyper-reflective material * No serous pigment epithelium detachments \>100 microns in height Exclusion Criteria: * Females who are pregnant, nursing, planning a pregnancy during the study or who are of childbearing potential not using a reliable method of contraception and/or not willing to maintain a reliable method of contraception during their participation in the study. Women of childbearing potential with a positive urine pregnancy test administered at baseline are not eligible to receive study drug. * Participation in an investigational drug or device study within 90 days of screening * Subjects with active exudative AMD in the fellow eye * Subjects who had anti-VEGF IVT in either eye in the past 90 days * Subjects with pigment epithelium detachments * Subjects with active exudative AMD * Subjects with any prior retina surgery * Subjects with pathology that could prevent observation and follow-up of macular structures and measurement of BCVA (i.e. advanced primary open angle glaucoma, any stage of normal tension glaucoma and corneal opacification) * Subjects that are likely to require cataract surgery in the opinion of the investigator within the study protocol period